South Korean drugmaker Celltrion Inc on Monday announced positive results for its experimental antibody COVID-19 treatment that it said was safe and reduced the treatment period by nearly five days in Phase 3 global clinical trials.
The trials, which involved 1,315 participants, have taken place since January in 13 countries, including in South Korea, the US, Spain and Romania, Celltrion said in a statement.
The treatment slowed severe symptoms of COVID-19 in more than 70 percent of patients, including the high-risk group with underlying conditions. It also cut the recovery period by 4.9 days, the company said.
In February South Korea, granted conditional approval to the antibody treatment, making it the first locally made coronavirus treatment in the country to win such approval. The company said it would seek full authorization based on the trial results.
Celltrion shares rose as much as 5.6 percent in Monday morning trade, compared with a 0.3 percent drop in the wider market.
UAE scientists injecting ‘immune’ camels with COVID-19 to study virus antibodiesA United Arab Emirates scientist is spearheading a study looking at how camels – immune to the COVID-19 virus – could provide vital answers into how ... Coronavirus
Baby born with COVID-19 antibodies in Singapore: ReportA Singaporean woman, who was infected with the coronavirus in March when she was pregnant, has given birth to a baby with antibodies against the virus ... Coronavirus
UAE administers ‘booster’ shot to those with no COVID-19 antibodies after vaccineSome people in the United Arab Emirates were given a third coronavirus “booster” shot after receiving two doses of a vaccine because they had not ... Coronavirus